Some of the regulators affected by this treatment however could be implicated in anti-tumorigenic activities (i.e., IL-6 (Jiang et al., 2011)), yet modulation identified in other regulators are potentially implicated in prostate cancer tumorigenesis, such as BHLHE40 (Dmitriev et al., 2015), and SRF (Prencipe et al., 2018). The gene discussed is IL6; the disease is prostate cancer.